Astrazeneca Ab

Zeneca Limited

Zeneca Pharma S. A.

Other

Astra Zeneca U.k. Limited

Patrick Ple

Laurent Francois Andre Hennequin

Christine Marie Paul Lambert-Van Der Brempt

Graham C Crawley

Thomas G Bird

Darren Mckerrecher

Sebastien Louis Degorce

Christine Marie Paul Lambert

Remy Robert Morgentin

Andrew Peter Thomas

Bernard Barlaam

Jean-Jacques Marcel Lohmann

Laurent F A Hennequin

Frederic H Jung

Michael S Large

Bernard Christophe Barlaam

Jeffrey Philip Poyser

Laurent François André Hennequin

Elaine S E Stokes

Kevin Michael Foote

Clifford David Jones

Bernard Chistrophe Barlaam

Christine M P Lambert

Sebastien Louis Degeorge

Christine Marie Lambert-Van Der Brempt

The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R, R, R, R, R, R, R, R, n and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Chromenone derivatives

The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer. 

Pyridine compounds

The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R, R, R, R, R, n and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

The invention relates to the use of compounds of formula (I) and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. 

Quinazoline derivatives as angiogenesis inhibitors

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X, p, R, q, R, R, R, R, Ring A, r and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability. 

Quinazoline derivatives

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X, p, R, q, R, R, R, R, Ring A, r and Rhas any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

Quinoline derivatives

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q, Z, m, R, R, Rand Qhave any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease. 

Quinazoline derivatives for the treatment of tumours

The invention concerns the use of a quinazoline derivative of Formula (I) wherein Qincludes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q&#x2014;X&#x2014; wherein Xincludes a direct bond and O and Qincludes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of Rand Ris hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Qincludes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human. 

Method of producing an antiangiogenic or vascular permeability reducing effect

The invention concerns quinazoline derivatives of Formula (I): (A chemical formula should be inserted here&#x2014;please see paper copy enclosed herewith) wherein Z is an O, S, SO, SO, N(R) or C(R)group wherein each Rgroup is hydrogen or (1-8C) alkyl, m is 0, 1, 2 or 3, each Rgroup is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, n is 0, 1, 2 or 3, and each Rgroup is selected from halogeno, (1-8C) alkyl, (1-6C) alkoxy and any of the other meanings defined in the description, or pharmaceutically-acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease. 

Quinazoline derivatives as Src tyrosine kinase inhibitors

The invention concerns quinazoline derivatives of Formula I (A Chemical Formula should be inserted here&#x2014;please see paper copy enclosed) wherein each of Z, m, R, n and Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumor disease.

The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R, n, Rand Rhave any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1&#x2013;3 heteroatoms selected independently from O, N and S; Z is &#x2014;O&#x2014;, &#x2014;NH&#x2014;, &#x2014;S&#x2014;, &#x2014;CH&#x2014; or a direct bond; n is 0&#x2013;5; m is 0&#x2013;3; Rrepresents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, Calkyl, Calkoxy, Calkylsulphanyl, &#x2014;NRR(wherein Rand R, which may be the same or different, each represents hydrogen or Calkyl), or RX&#x2014; (wherein Xand Rare as defined herein; Rrepresents hydrogen, oxo, halogeno, hydroxy, Calkoxy, Calkyl, Calkoxymethyl, Calkanoyl, Chaloalkyl, cyano, amino, Calkenyl, Calkynyl, Calkanoyloxy, nitro, Calkanoylamino, Calkoxycarbonyl, Calkylsulphanyl, Calkylsulphinyl, Calkylsulphonyl, carbamoyl, N&#x2014;Calkylcarbamoyl, N,N-di(Calkylcarbamoyl, aminosulphonyl, N&#x2014;Calkylaminosulphonyl, N,N-di(Calkyl)aminosulphonyl, N&#x2014;(Calkylsulphonyl)amino, N&#x2014;(Calkylsulphonyl)-N&#x2014;(Calkyl)amino, N,N-di(Calkylsulphonyl)amino, a Calkylene chain joined to two ring C carbon atoms, CalkanoylaminoCalkyl, carboxy or a group RX(wherein Xand Rare as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. 

Growing community of inventors

Reims, France

Patrick Ple